Atea Pharmaceuticals Inc. has completed enrollment of more than 880 treatment-naïve patients in its C-BEYOND Phase 3 trial, which is evaluating the fixed-dose combination regimen of bemnifosbuvir and ruzasvir compared to sofosbuvir and velpatasvir for the treatment of hepatitis C virus (HCV). The C-BEYOND trial is being conducted at approximately 120 clinical sites across the US and Canada. Topline results from this study are expected to be reported in mid-2026. Additionally, the company is advancing the C-FORWARD Phase 3 trial, evaluating the same combination regimen in up to 17 countries outside North America. Enrollment completion for C-FORWARD is anticipated by mid-2026, with topline results expected by year-end 2026. In both studies, bemnifosbuvir and ruzasvir are administered orally once daily for 8 weeks (in patients without cirrhosis) or 12 weeks (in patients with compensated cirrhosis), while the comparator regimen is given for 12 weeks. Results have not yet been presented.